Rigel Pharmaceuticals (RIGL) Interest & Investment Income (2010 - 2026)

Rigel Pharmaceuticals' Interest & Investment Income history runs 17 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• On a quarterly basis, Interest & Investment Income rose 103.89% year-over-year to $1.2 million in Q1 2026; TTM through Mar 2026 was $4.3 million, a 105.5% increase from a year earlier, with the FY2025 full-year figure at $3.7 million, up 75.96% from the prior year.
• Interest & Investment Income retreated to $1.2 million in Q1 2026 per RIGL's latest filing, from $1.2 million in the prior quarter.
• Across five years, Interest & Investment Income topped out at $1.2 million in Q4 2025 and bottomed at $21000.0 in Q1 2022.
• The 5-year median for Interest & Investment Income is $552000.0 (2024), against an average of $584352.9.
• Across the five-year window, Interest & Investment Income soared 2581.25% in 2022 and sank 36.76% in 2024, its largest moves.
• Year by year, Interest & Investment Income stood at $429000.0 in 2022, then surged by 58.04% to $678000.0 in 2023, then dropped by 23.01% to $522000.0 in 2024, then surged by 138.12% to $1.2 million in 2025, then dropped by 3.06% to $1.2 million in 2026.
• Per Business Quant, the three latest RIGL Interest & Investment Income figures stand at $1.2 million (Q1 2026), $1.2 million (Q4 2025), and $1.1 million (Q3 2025).